New research on CRISPR techniques that could provide treatments and improved diagnostics for several major viruses and other medical conditions is pushing valuations higher in the gene editing industry. Ailments like Cancer, HPV, and HIV are increasingly being targeted with an increasingly sophisticated CRISPR toolbox that has already managed to beat the street when commercialized by companies like Novartis

To read this Market Insight, you’ll need to  sign in

If you don’t have a subscription,  get in touch  for a free trial.